About Allay Therapeutics
Allay Therapeutics is a company based in Menlo Park (United States) founded in 2017. Allay Therapeutics has raised $146.89 million across 6 funding rounds from investors including Evonik, HHS and Temasek. Allay Therapeutics offers products and services including Localized Pain Management Technology. Allay Therapeutics operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
- Headquarter Menlo Park, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Allay Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$146.89 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
Evonik
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Allay Therapeutics
Allay Therapeutics offers a comprehensive portfolio of products and services, including Localized Pain Management Technology.
Technology designed to provide weeks of targeted pain relief for patients.
People of Allay Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Allay Therapeutics
Allay Therapeutics has successfully raised a total of $146.89M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Allay Therapeutics
Allay Therapeutics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Evonik, HHS and Temasek.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare venture capital investments are made by Arboretum Ventures.
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
An investment platform is provided for diverse sectors and geographies.
|
Locked | Locked | Locked |
Investor details for Allay Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Allay Therapeutics
Investment portfolio details for Allay Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Allay Therapeutics
Detailed financials for Allay Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Allay Therapeutics Comparisons
Peer comparison for Allay Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Allay Therapeutics
Allay Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| Locked | Locked | Locked |
Pain treatment products are developed through reformulation technologies.
|
Detailed competitors of Allay Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Allay Therapeutics
Complete news archive for Allay Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allay Therapeutics
Allay Therapeutics was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Allay Therapeutics is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Allay Therapeutics is a funded company, having raised a total of $146.89M across 6 funding rounds to date.
Allay Therapeutics was founded in 2017 in Menlo Park, United States, within the biotechnology sector. Drugs for post-surgical pain management are developed through a proprietary platform that integrates non-opioid analgesics with biopolymers, resulting in dissolvable candidates for site-targeted relief. The lead candidate, ATX-101, is aimed at knee rehabilitation following surgery. Additional injectables, ATX-201 and ATX-301, are created for on-demand pain control.
Allay Therapeutics's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
Allay Therapeutics offers Localized Pain Management Technology.
Allay Therapeutics has 11 investors. Key investors include Evonik, HHS, Temasek, Arboretum Ventures, and NEA.